Login or sign up
For business
Average ratingGreat
4.1/ 5

Based on 11 reviews

536%
436%
327%
20%
10%
Ask AI

Ask Trustburn about Pharvaris

Based on 11 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Pharvaris

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.

The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.